Skip to main content
Robert Diasio, MD, Oncology, Rochester, MN

RobertBDiasioMD

Oncology • Rochester, MN

Clinical Pharmacology

Director, Mayo Clinic Cancer Center; William J. and Charles H. Mayo Professor, Professor, Pharmacology and Oncology, Mayo Medical School

Join to view full profile

Dr. Diasio is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Diasio's full profile

Already have an account?

  • Office

    200 1st St Sw
    Rochester, MN 55905
    Phone+1 507-284-2511

Summary

  • My basic research interest has focused mainly on the area of cancer pharmacogenetics/pharmacogenomics. My contributions have included the initial clinical and pharmacologic characterization of the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency. More recently research in my lab has helped to characterize the molecular basis for DPD deficiency and to develop genomic tests to predict DPD deficiency.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1973 - 1976
  • University of Rochester
    University of RochesterResidency, Internal Medicine, 1971 - 1973
  • Yale School of Medicine
    Yale School of MedicineClass of 1971

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 1984 - 2018
  • VA State Medical License
    VA State Medical License 1976 - 2012

Awards, Honors, & Recognition

  • Elected Member Association of American Physicians, 2002
  • American Society for Clinical Investigation 1998
  • Fellow American Association for Advancement of Science

Publications & Presentations

PubMed

Press Mentions

  • Her Cancer Surgery Was a Success. Then a Genetic Condition Let a Chemo Drug Ravage Her Body
    Her Cancer Surgery Was a Success. Then a Genetic Condition Let a Chemo Drug Ravage Her BodyNovember 13th, 2019
  • Mayo Clinic Cancer Center Renews Research Funding from the National Cancer Institute
    Mayo Clinic Cancer Center Renews Research Funding from the National Cancer InstituteSeptember 11th, 2019
  • Mayo Clinic Cancer Center Renews National Cancer Institute Research Funding
    Mayo Clinic Cancer Center Renews National Cancer Institute Research FundingSeptember 9th, 2019
  • Join now to see all

Grant Support

  • Mayo Clinic Cancer CenterNational Cancer Institute2014–Present
  • Mayo Comprehensive Cancer Center GrantNational Cancer Institute2006–2012
  • SupplementNational Cancer Institute2009–2010
  • Screening For Decreased 5-Fluorouracil CatabolismNational Cancer Institute2006–2010
  • Dihydropyrimidine Dehydrogenase (DPD) Deficiency In Population StudiesNational Center For Research Resources2005–2007
  • Genetic Polymorphism Of Dihydropyrimidine DehydrogenaseNational Cancer Institute1994–2006
  • Molecular Approach In Predicting 5-Fluorouracil EfficacyNational Cancer Institute2005
  • Molecular Approach In Predicting 5-Fluorouracil EfficacyNational Cancer Institute2002–2005
  • Genetic Polymorphism Of Dpd: Ident. Of DPD DeficiencyNational Center For Research Resources2004
  • Molecular Approach In Predicting 5 Fluorouracil EfficacyNational Cancer Institute2001
  • Pharmacokinetic &Metabolic Evaluation Of 5FU In The Presence Of Oral 776c85National Center For Research Resources1998–2000
  • National Cancer Institute Initial Review GroupNational Cancer Institute1996–1999
  • Oral BCX 34 In T Cell MaliganciesNational Center For Research Resources1998
  • Chronic Oral 5-FU In Combination With 776c85National Center For Research Resources1996–1997
  • BCX 34 In T Cell MaliganciesNational Center For Research Resources1996–1997
  • Cancer And Leukemia Group BNational Cancer Institute1995–1997
  • Oral Sorivudine, Bvu &Dpd Activity In Peripheral Blood Mononuclear CellsNational Center For Research Resources1996
  • Anti B4 Blocked Ricin In B Lineage All/High Dose Cytarabin In NON B Lineage AllNational Center For Research Resources1996
  • Clinical Pharmacology Of IVX-E-59 In HIV Using (2-14c)Azt-P(2'3-3h)DdiNational Center For Research Resources1995
  • DDTC As A Protective Agent Against Cisplatin ToxicitiesNational Center For Research Resources1992–1995
  • 5-FU And Radiolabled Zidovudine (3h-Azt) In Colorectal CancerNational Center For Research Resources1992–1995
  • Examination Of The Metabolism Of 5-Fluorouracil In ManNational Center For Research Resources1990–1995
  • Biochemical Pharmacologic Studies Of Anticancer And Antiviral DrugsNational Center For Research Resources1990–1995
  • Mechanism Of Toxicity Of Fluorocytosine And FluorouracilNational Cancer Institute1987–1994
  • Continuous IV Infusion Of FUDR In Patients With Metastatic CarcinomaNational Center For Research Resources1990
  • Mechanism Of Toxicity Of Fluorocytosine And FluorouracilNational Cancer Institute1985–1987

Professional Memberships

Dr. Robert Diasio, Dr. Robert Diasio, MD, Dr. R Diasio, Dr. Robert B Diasio